Wall Street analysts expect Sesen Bio Inc (NASDAQ:SESN) to announce ($0.07) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Sesen Bio’s earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.08). Sesen Bio reported earnings per share of ($0.37) during the same quarter last year, which would indicate a positive year over year growth rate of 81.1%. The company is expected to issue its next quarterly earnings report on Monday, November 19th.
According to Zacks, analysts expect that Sesen Bio will report full year earnings of ($0.39) per share for the current fiscal year, with EPS estimates ranging from ($0.41) to ($0.36). For the next financial year, analysts expect that the company will post earnings of ($0.28) per share, with EPS estimates ranging from ($0.32) to ($0.23). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Sesen Bio.
Sesen Bio (NASDAQ:SESN) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03).
Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp bought a new position in shares of Sesen Bio in the second quarter valued at approximately $147,000. MYDA Advisors LLC bought a new position in shares of Sesen Bio in the second quarter valued at approximately $195,000. DRW Securities LLC bought a new position in shares of Sesen Bio in the second quarter valued at approximately $293,000. Northern Trust Corp bought a new position in shares of Sesen Bio in the second quarter valued at approximately $315,000. Finally, AJ Wealth Strategies LLC bought a new position in shares of Sesen Bio in the second quarter valued at approximately $400,000. Institutional investors own 52.07% of the company’s stock.
Shares of SESN stock traded up $0.05 during trading hours on Tuesday, reaching $1.78. The company had a trading volume of 371,600 shares, compared to its average volume of 2,237,448. Sesen Bio has a 12 month low of $0.62 and a 12 month high of $3.50. The firm has a market capitalization of $165.57 million, a PE ratio of -1.60 and a beta of 2.60.
About Sesen Bio
Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.
Featured Story: Technical Analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.